Hey there, time traveller! This article was published 12/6/2019 (399 days ago), so information in it may no longer be current.
OTTAWA - Canada's governments have to work together to transform, rather than tinker with, a patchwork of prescription-drug plans to create a public plan for every Canadian, says the chair of the expert panel the federal Liberals named to advise them how to create a national pharmacare system.
The patchwork should be replaced by a pharmacare system much like the public health-care system, with standards set by the federal government and supported by federal funding, but administered by provincial and territorial governments, the panel said in its final report Wednesday. Individuals should still be able to get supplemental drug insurance, either on their own or through workplace benefits programs.
Dr. Eric Hoskins, an Ontario health minister under the previous provincial Liberal government, released his council's findings in Ottawa. The group reported that such a plan will result in savings of an estimated $5 billion annually, an average of $350 a year for each family.
Canadians spent $34 billion on prescription medicines in 2018, the report says, adding drugs are the second-biggest expenditure in health care after hospitals. The cost is growing, as well, as people live longer with chronic conditions that require medication.
It is a good time to show courage and do some "nation-building," Hoskins said at a press conference as he put forward his plan, adding the price of doing nothing is too high.
"If we want to put in place a national pharmacare program, the federal government has to play a leadership role but also we have to make sure that we have all provinces and territories at the table." –Health Minister Ginette Petitpas Taylor
Canada has a variety of drug plans administered by provinces, mainly for children, seniors and people on social assistance. Other plans managed by the federal government cover other groups, such as Indigenous people and members of the military, while private insurance fills the gaps for some.
Hoskins' panel recommended Wednesday that a new drug agency be responsible for developing a national list of prescription drugs, known as a formulary, beginning with common or so-called essential medicines by Jan. 1, 2022. It also suggests the initial formulary expand to a "fully comprehensive formulary" no later than Jan. 1, 2027. Each government with its own smaller drug-coverage programs now does this for itself.
Speaking outside the House of Commons on Wednesday, Health Minister Ginette Petitpas Taylor said she would review the recommendations and pledged to work with provinces, territories, stakeholders and partners as Ottawa considers next steps.
One of the key questions is money.
The report calls for the federal government to work with the provincial and territorial governments to begin to implement national pharmacare as soon as possible, with a new financing agreement to be developed jointly and with Ottawa paying the additional costs governments would take on.
Hoskins' report estimated that annual incremental costs will reach $15.3 billion in 2027. The advisory council recognizes the "very significant fiscal implications" but stressed "the issue is too important to ignore."
"You will excuse me if I have zero confidence in [the federal government's] ability to manage this." –Conservative Leader Andrew Scheer
The federal government also recognizes funding is going to have to be part of the equation, Petitpas Taylor said Wednesday, and it doesn't expect provinces to foot the bill.
"If we want to put in place a national pharmacare program, the federal government has to play a leadership role but also we have to make sure that we have all provinces and territories at the table," she said. "Does that mean it will happen all at once, that all provinces and territories will be at the table at once? Not necessarily."
In response to the report, Conservative Leader Andrew Scheer took aim at Hoskins as a former minister in Kathleen Wynne's government in Ontario.
"Justin Trudeau hired someone from a disastrous provincial Liberal government that spent Ontario into the ground with unsustainable rates of spending growth," he said. "You will excuse me if I have zero confidence in their ability to manage this."
For its part, the federal NDP urged the Liberals to act on implementation.
"Dr. Hoskins and the advisory council have come to the same conclusion as every other expert panel and study done on the subject: prescription-drug coverage should be integrated into our public health-care system to cover everyone," NDP Leader Jagmeet Singh said in a statement.
"Dr. Hoskins and the advisory council have come to the same conclusion as every other expert panel and study done on the subject: prescription–drug coverage should be integrated into our public health–care system to cover everyone." –NDP Leader Jagmeet Singh said in a statement.
Organizations including the Heart and Stroke Foundation and the Canadian Labour Congress also issued statements to applaud the recommendations.
The latest updates on the novel coronavirus and COVID-19.
Action Canada for Sexual Health and Rights, a pro-choice charitable organization, said it is pleased to see the call for a universal, single-payer system but said it is concerned a phased approach of prioritizing commonly used drugs might not include sexual- and reproductive-health medications.
Wednesday's report also suggests "co-payments" expected from individuals be limited to $2 per prescription for essential medicines and $5 per prescription for all other drugs on the national formulary, with an annual limit of $100 per household.
It says those living with disabilities, people on social assistance and low-income seniors should be exempt from these fees.
In its last budget, the Liberal government pledged to create a new agency to buy drugs in bulk and cut Canadian medication costs as the first step toward a national drug plan.
It said it intends to work with provinces, territories and other partners to develop the mandate for the agency, with Health Canada to receive $35 million over four years starting in 2019-2020 to create an office to support the plan. It also promised to spend $500 million a year beginning in 2022 on subsidizing drugs that treat rare diseases.
—Follow @kkirkup on Twitter
Highlights from the report on national pharmacare
OTTAWA - An expert panel is calling for a universal, single-payer national pharmacare plan. Here's what it recommends:
— The federal government should work with provinces and territories to create a national pharmacare program that works like public health care, in that it is "universal, comprehensive, accessible, portable and public."
— National pharmacare should be delivered by provinces and territories, governed by federal legislation and supported by federal funding in line with "agreed-upon national standards."
— The federal government should work with the provincial and territorial governments to begin to implement national pharmacare as soon as possible, with a new financing agreement to be developed jointly by governments and with Ottawa paying the incremental costs.
— Federal, provincial and territorial governments should work together to create an arm's-length drug agency to oversee national pharmacare, with its first task to be creating a list of drugs to be covered by the plan
— The initial formulary should be chosen from a list of essential medicines covering most major conditions, representing half of prescriptions, to be made available through national pharmacare by Jan. 1, 2022.
— A strategy and plan for funding access to expensive drugs for rare diseases to be implemented by Jan. 1, 2022.
— Co-payments under the plan should be limited to $2 per prescription for essential medicines and $5 per prescription for all other drugs on the national formulary with an annual limit of $100 per household. It says those living with disabilities, people on social assistance and low-income seniors should be exempt from these payments.